☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
johnson & johnson
Johnson & Johnson Reports New Long-Term Data from P-III (MARIPOSA) Trial of Rybrevant Plus Lazcluze for Advanced NSCLC
September 9, 2024
Johnson & Johnson Reports Nipocalimab’s BLA Submission to the US FDA for Treating Generalized Myasthenia Gravi
August 30, 2024
Johnson & Johnson’s Balversa (Erdafitinib) Receives the EC’s Approval to Treat Urothelial Carcinoma
August 26, 2024
Johnson & Johnson Reports the US FDA’s Approval of Rybrevant + Lazcluze as a 1L Treatment of NSCLC with EGFR Mutations
August 21, 2024
Johnson & Johnson’s Darzalex Faspro Quadruplet Combination Gains the US FDA’s Approval to Treat Multiple Myeloma (MM)
July 31, 2024
Johnson & Johnson’s Yuvanci (macitentan and tadalafil) Receives the CHMP’s Positive Opinion for Treating Pulmonary Arterial Hypert...
July 26, 2024
Load more...
Back to Home